About Windtree Therapeutics (WINT)

Windtree Therapeutics, Inc., also known as Windtree or WINT, is a biotechnology company focused on developing novel therapeutics to meet the needs of patients with respiratory and inflammatory diseases. The company's primary product candidate is istaroxime, a novel agent being developed for the treatment of acute heart failure. Istaroxime has demonstrated positive results in early-stage clinical trials, showing potential to improve cardiac function and reduce symptoms in patients with acute heart failure. The company is currently conducting additional clinical studies to further evaluate the safety and efficacy of istaroxime. In addition to istaroxime, Windtree is also developing another product candidate, rostafuroxin, for the treatment of hypertensive disorders. Rostafuroxin is a first-in-class compound that targets a specific enzyme involved in blood pressure regulation. Windtree is committed to advancing these innovative therapies through clinical development and regulatory approval to ultimately improve patient outcomes in these indications.

As of the latest available data, Windtree's market capitalization is approximately $XX million. This reflects the total value of the company's outstanding shares of common stock. Market capitalization is an important metric in assessing the size and value of a company in the stock market. It is calculated by multiplying the current share price by the total number of outstanding shares. Windtree's market capitalization is subject to change based on fluctuations in its stock price and the number of shares outstanding.